MedVi vs MyStart: Compare GLP-1 Programs & Pricing
Side-by-side MedVi and MyStart: semaglutide/tirzepatide starting prices, promos, membership rules, and official links.
MedVi and MyStart are telehealth providers offering GLP-1–based weight management and metabolic care. This comparison focuses on starting prices for compounded semaglutide and tirzepatide, promotional offers, membership requirements, medical oversight, and safety considerations to help you decide which service may better match your needs.
MedVi vs MyStart: Quick Overview
| Provider | Semaglutide | Tirzepatide | Promo | Membership |
|---|---|---|---|---|
| MedVi | $179.00 | $279.00 | $120 off first month | No |
| MyStart | $179.00 | $299.00 | (Code: EXPLORE2026) | — |
MedVi vs MyStart: Medical Process & Accessibility
MedVi typically emphasizes fast telehealth intake and clinician review. New patients complete an online intake, medical history, and virtual consultation; if clinically appropriate, a licensed prescriber may write a prescription and coordinate dispensing with a partnered U.S. pharmacy. MyStart follows a similar telehealth workflow but highlights structured follow-ups and dose adjustments to support individual response and tolerability.
MedVi vs MyStart: Pricing Comparison
Both providers list semaglutide starting at $179.00. For tirzepatide, MedVi lists $279.00 while MyStart lists $299.00 — MedVi’s tirzepatide price is the lower option. MedVi advertises a promotional discount of $120 off the first month; MyStart promotes a discount via code EXPLORE2026. Always confirm current pricing and promo eligibility on each provider’s site before enrolling.
Compare Current MedVi Pricing Compare Current MyStart Pricing
MedVi vs MyStart: Clinical Oversight & Follow-up
Both platforms connect patients with licensed clinicians who evaluate medical history, contraindications, and concomitant medications. Telehealth clinicians will determine whether GLP-1–based therapy is appropriate and provide monitoring plans. Follow-up frequency, lab ordering, and dose titration policies vary — MyStart places more emphasis on planned follow-ups, while MedVi positions itself for quicker onboarding with standard remote monitoring.
Book a Consultation with MedVi
MedVi vs MyStart: Medication Quality & Safety
Both services coordinate dispensing via accredited U.S. pharmacies. Many telehealth providers offer compounded versions of semaglutide or tirzepatide; these are not identical to branded, FDA‑approved products. Branded GLP-1 and GIP/GLP-1 medicines are FDA‑regulated and have established labeling; compounded preparations are made under different standards. Patients should discuss risks, potential side effects (nausea, GI symptoms, rare adverse events), and contraindications with a clinician before starting therapy.
Learn About MyStart Safety Processes
MedVi vs MyStart: Customer Experience & Delivery
Users report MedVi often scores well for affordability and speed of initiation, while MyStart receives praise for attentive follow-up and dose optimization. Both typically arrange shipment of medication within days to a week after prescription approval, depending on pharmacy processing and your location. Read recent reviews and check refund or resupply policies before ordering.
Read MedVi Reviews Read MyStart Reviews
MedVi vs MyStart: Final Verdict
Choose MedVi if cost and fast onboarding are top priorities — it lists the lower tirzepatide price and a first‑month discount. Choose MyStart if you prefer more structured follow-ups and an emphasis on personalized dose titration. Both are telehealth-based programs that work with licensed clinicians and pharmacies to provide access to GLP‑1 therapies, but they are not a substitute for in‑person medical evaluation when clinically indicated.
Join MedVi Get Started with MyStart
Disclaimer
This article is informational only and does not constitute medical advice. Always consult a licensed clinician before starting any medication. Pricing, promotions, and membership rules can change; confirm details directly with each provider. Some links on this page are referral links that may provide compensation to the publisher.